The Silent Prelude to Parkinson’s: Robert Sapolsky on Anosmia and the Brain’s Hidden Vulnerability

 One of the most unsettling facts about Parkinson’s disease is that the brain may begin deteriorating years, sometimes decades, before the first visible tremor appears. Long before a patient struggles to initiate movement or develops muscular rigidity, another symptom may quietly emerge: the loss of smell, known as anosmia.

According to Robert Sapolsky, this early sensory change offers a fascinating and disturbing clue into how Parkinson’s disease may begin. The inability to smell is not merely an unrelated symptom; it may represent the earliest stage of a slow neurological invasion already underway inside the brain.

Parkinson’s disease is fundamentally a movement disorder centered around a region deep in the brain called the substantia nigra. This structure relies heavily on dopamine, a neurotransmitter involved in initiating smooth, coordinated movement. Dopamine itself is not dangerous, but its normal breakdown during cellular metabolism produces small amounts of reactive oxygen molecules, commonly called oxygen radicals.

Ordinarily, the brain neutralizes these radicals using antioxidants. But the substantia nigra contains unusually high levels of iron, and this creates a dangerous biochemical environment. In the presence of iron, relatively harmless oxygen radicals can be converted into highly destructive forms that damage and eventually kill dopamine-producing neurons. As these neurons die, the classic motor symptoms of Parkinson’s gradually appear: slowed movement, rigidity, tremors, and eventually severe physical disability.

A small percentage of Parkinson’s cases are clearly genetic. Certain inherited mutations virtually guarantee the disease, often causing earlier onset and more aggressive progression. But most Parkinson’s cases are not directly caused by genes alone. Instead, researchers increasingly view the disease as the result of a gene-environment interaction: a combination of biological vulnerability and environmental exposure.

This is where anosmia becomes important.

Sapolsky points to evidence linking Parkinson’s disease to environmental neurotoxins, particularly pesticides, industrial solvents, welding fumes, and compounds produced through industrial processes. Certain chemicals, such as paraquat and related toxins, appear especially damaging because they intensify oxidative stress inside the substantia nigra.

The crucial question becomes: how do these toxins reach the brain?

One major route is inhalation.

When toxic particles are inhaled through the nose, they first encounter the olfactory system, the neural machinery responsible for smell. Damage to this system can produce anosmia years before any motor symptoms appear. But the process may not stop there. According to the theory Sapolsky describes, these toxins may slowly travel deeper into the brain over many years, eventually reaching the substantia nigra where they inflict their greatest damage.

In this framework, the loss of smell is not simply collateral damage. It may be the first observable marker of a long neurodegenerative journey already in progress.

Another possible route involves ingestion. Environmental toxins consumed through contaminated food or water may enter the digestive system and gradually travel upward through the vagus nerve, a major communication pathway connecting the gut and brain. Intriguingly, some patients who later develop Parkinson’s report gastrointestinal disturbances years before diagnosis. Research has also shown that people who underwent vagotomy procedures—surgical severing of the vagus nerve—appear to have a reduced risk of developing Parkinson’s, further supporting the gut-brain connection.

Together, these findings suggest that Parkinson’s disease may begin far outside the regions traditionally associated with movement. The earliest signs may emerge in the nose or gut long before the disease reaches the dopamine circuits responsible for motor control.

Importantly, this theory does not explain every case of Parkinson’s disease. Only a subset of patients experience early anosmia or gastrointestinal symptoms. Parkinson’s remains a complex condition with multiple possible causes and pathways. Still, the idea that a subtle sensory loss could foreshadow a devastating neurological illness years in advance has transformed how scientists think about the disease.

For decades, Parkinson’s was understood primarily as a disorder of movement. Today, researchers increasingly see it as a slow-moving systemic process that may begin silently and invisibly long before diagnosis.

The tragedy of anosmia in this context is not simply the loss of smell itself. It may represent the brain’s earliest warning signal that a neurodegenerative process has already begun.

Loss of Smell - Parkinsons - Robert Sapolsky
Question 2 (Parkinson’s smell loss) https://www.youtube.com/watch?v=b5YuuSOH5Vk&t=1325s

© 2000-2030 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a five-year copyright. Library of Congress Card Number: LCN 00-192742 ISBN: 0-9703195-0-9